T2 Biosystems, Inc.
TTOO
$0.1035
-$0.0125-10.78%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -30.19% | -45.74% | -58.15% | -67.75% | -53.80% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -30.19% | -45.74% | -58.15% | -67.75% | -53.80% |
| Cost of Revenue | -17.19% | -30.95% | -31.81% | -37.07% | -34.96% |
| Gross Profit | 10.37% | 23.07% | 13.88% | 9.04% | 17.27% |
| SG&A Expenses | -12.57% | -13.69% | -15.42% | -18.92% | -14.65% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -15.24% | -23.58% | -25.04% | -29.74% | -27.03% |
| Operating Income | 11.75% | 17.95% | 14.49% | 14.34% | 15.64% |
| Income Before Tax | 13.81% | 6.80% | 28.09% | 19.23% | 22.19% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 13.81% | 6.80% | 28.09% | 19.23% | 22.19% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 13.81% | 6.80% | 28.09% | 19.23% | 22.19% |
| EBIT | 11.75% | 17.95% | 14.49% | 14.34% | 15.64% |
| EBITDA | 10.33% | 17.18% | 14.11% | 14.27% | 15.90% |
| EPS Basic | 97.87% | 98.45% | 98.51% | 89.83% | 83.12% |
| Normalized Basic EPS | 97.81% | 98.52% | 98.54% | 90.16% | 83.60% |
| EPS Diluted | 97.87% | 98.45% | 98.51% | 89.83% | 83.12% |
| Normalized Diluted EPS | 97.81% | 98.52% | 98.54% | 90.16% | 83.60% |
| Average Basic Shares Outstanding | 665.02% | 2,552.30% | 4,918.24% | 5,004.27% | 3,278.55% |
| Average Diluted Shares Outstanding | 665.02% | 2,552.30% | 4,918.24% | 5,004.27% | 3,278.55% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
